Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nitrase Therapeutics

Explore full profile

The NITROME platform allows us to elucidate the biology of nitrases and delivers novel therapeutics for a wide variety of diseases

South San Francisco, United StatesFounded 2012Health
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Nitrase Therapeutics and the history behind them.

About Nitrase Therapeutics

Nitrase Therapeutics is a pioneering biotechnology company that focuses on the discovery and development of novel therapeutics based on nitrase biology. Utilizing its proprietary NITROME Platform, the company leverages its unique knowledge of protein nitration to identify new nitrases, their nitro substrates, and their roles in various diseases. This platform enables the elucidation of nitrase biology, leading to the creation of innovative treatments for a broad spectrum of diseases.

Nitrase Therapeutics primarily serves the pharmaceutical and healthcare sectors, targeting unmet medical needs through its cutting-edge research and development. The company operates in the biotechnology market, which is characterized by high innovation and significant investment in R&D. Its business model revolves around the development and commercialization of nitrase-based drugs, generating revenue through partnerships, licensing agreements, and eventual product sales.

Key clients include pharmaceutical companies, research institutions, and healthcare providers looking for advanced therapeutic solutions. By focusing on the biology of nitrases, Nitrase Therapeutics aims to unlock new pathways for treating diseases that currently lack effective treatments.

Source: Dealroom company data

At a glance

Founded
2012
Headquarters
South San Francisco, United States
Sector
Health

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Michael J. Fox Foundation for Parkinson's Research

Series A4 investors entered at this stage

  • AbbVie
  • SV Health Investors
  • Alexandria Equities
  • Bristol-Myers Squibb
Employees 19 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · South San Francisco HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Nitrase Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nitrase Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.